The objective of this study was to identify patterns of fever and neutropenia in pediatric patients undergoing initial hospitalization for hematopoietic stem cell transplantation. A retrospective review of 75 HSCTs over a 4-year period at a single institution was performed, of which 68% were allogeneic and 32% were autologous. Stem cell sources included bone marrow (29%), PBSC (52%) and umbilical cord blood (16%). Fever occurred in 74 (98%) of the episodes. Unexplained fever (FUO) occurred in 43%. Bacteremia without an anatomic focus occurred in 29%, while CVC associated infections occurred in 17%. In 49% of transplants at least one blood culture was positive. The incidence of bacteremia was higher in allogeneic HSCTs (58%) than in autologous transplants (29%). Gram-positive bacteria accounted for 71% of the isolates. Lower rates of bacteremia were observed in patients receiving oral fluoroquinolone prophylaxis. The median duration of fever was 12.5 days and time to engraftment 14 days. Regression analysis demonstrated that duration of fever was strongly associated with time to engraftment, and that time to engraftment was associated with source of cells and number of CD34 ؉ cells/kg administered. Recipients of autologous PBSC had the shortest durations of fever and time to engraftment, while recipients of allogeneic umbilical cord blood had the longest. Bone Marrow Transplantation (2000) 25, 59-65. Keywords: infection; bone marrow transplantation; neutropenia; pediatrics Hematopoietic stem cell transplantation (HSCT) is a common procedure in pediatric hematology/oncology. In 1997, it is estimated that 4000 allogeneic transplants and 1500 autologous transplants were performed for patients aged 20 years or less.
planted and in the composition of bone marrow/ hematopoietic stem cell grafts. 1 Cytokine mobilized peripheral blood stem cells and umbilical cord blood are increasingly used as alternatives to bone marrow as a source of HSCs. Unrelated donor HSCs are used more commonly. Increasing numbers of nonhematologic malignancies are treated with autologous HSC transplantation at least on an investigational basis. Because of these changes and the fact that pediatric transplant patients differ in age, comorbidities and underlying malignancies compared to adult transplant patients which have been more widely studied, we reviewed our recent experience with fever and neutropenia in pediatric HSCT.
Patients and methods
A retrospective review of the medical records for the initial hospitalization of all patients undergoing allogeneic or autologous HSCT in the Department of Pediatrics at the University of Texas MD Anderson Cancer Center from December 1994 to August 1998 was performed.
The majority of patients were treated according to a limited number of institutional protocols. Seventy-five percent of the autologous transplants were performed with a threedrug preparative regimen consisting of cyclophosphamide (7 g/m 2 ), thiotepa (750 mg/m 2 ) and melphalan (180 mg/m 2 ). 2 Forty-seven percent of the allogeneic transplants used a preparative regimen consisting of thiotepa (750 mg/m 2 ), busulfan (640 mg/m 2 ), and cyclophosphamide (120 mg/kg). 3 Ten percent used busulfan/cyclophosphamide, and 10% used cyclophosphamide/total body irradiation. Most of the remainder were cyclophosphamide based. Graft-versus-host disease prophylaxis for allogeneic transplants consisted of tacrolimus (0.03 mg/kg/day) (73%) or cyclosporin (3 mg/kg/day) (22%) with low-dose methotrexate (5 mg/m 2 on days 1, 3, 6 and 11). Transplants were performed in private rooms in a general pediatric oncology hospital unit. Rooms were equipped with HEPA-air filtration devices. Mask and glove isolation practices were employed when the patient's absolute neutrophil count (ANC) was below 500 cells/l. Gut decontamination with nonabsorbable antibiotics was not performed. Patients had external double or triple lumen central venous catheters placed by a pediatric surgeon 1-2 weeks prior to starting the preparative regimen. CVCs were used for blood sampling, as well as administration of medications and blood products. G-CSF (5 g/kg/day) was administered s.c. daily after infusion of graft until ANC Ͼ2000 cells/l. Intravenous gamma globulin (0.2-0.5 g/kg) was administered weekly. Patients received weekly dapsone or TMP/SMX for prophylaxis for Pneumocystis carinii pneumonia. Acyclovir was administered (15 mg/kg) daily until engraftment. Allogeneic recipients were monitored weekly for cytomegalovirus infection by shell vial or antigenemia methods. Allogeneic recipients with serologic evidence of prior CMV infection or those receiving grafts from CMV-positive donors received prophylactic ganciclovir (5 mg/kg daily) until day Ϫ1 and again once the ANC reached Ͼ1000 cells/l. In the latter part of the study period 23 patients received oral antibiotic prophylaxis starting when WBC was Ͻ1000 cells/l; 18 received ciprofloxacin alone, two received ciprofloxacin and penicillin (asplenic patients), two ciprofloxacin and amoxicillin/sulbactam, and one received trovafloxacin.
Fever was considered a single temperature Ͼ38.3°C or temperature Ͼ38.0°C for at least 6 h. Duration of fever was the period from the first recorded fever to the day the daily maximum temperature was Ͻ38°C and after which the patient remained afebrile. Blood cultures were performed from peripheral veins and from central venous catheters daily when patients were febrile. Chest X-rays and bacterial and/or viral cultures were performed only when clinically indicated. Catheter-related infections were identified by either local signs of infection at the catheter exit site or by CVC blood cultures with a greater colony count (Ͼ10:1) than those in simultaneous peripheral blood cultures. A 'set' of cultures is defined as those peripheral and CVC blood cultures drawn simultaneously.
Intravenous antibiotics were empirically administered when the patient became febrile. The practice in our unit during this period was to administer ceftazidime and a second antibiotic with additional gram-positive activity as initial empiric therapy (except in those circumstances in which allergy or clinically identified infections made other antibiotics more appropriate). 80% of cases had ceftazidime as part of the initial regimen; 64% of cases had vancomycin included in the initial treatment. In 1997 as part of a hospital-wide effort to control vancomycin resistant enterococci alternate gram-positive antibiotics (usually ampicillin/ sulbactam) were administered instead of initial empiric vancomycin. Empiric antifungal drugs (fluconazole or amphotericin B) were added when a patient remained febrile more than 3-7 days despite receiving broad spectrum antibacterial drug treatment.
Statistics
Statistical software (Statistica 5, StatSoft, Tulsa, OK, USA) was used to generate descriptive statistics and make statistical comparisons including ANOVA, multivariate regression analysis, Fisher's exact test (chi-squared test) and median tests. Non-normally distributed data were described using median as a measure of central tendency and the interquartile range (the range between the 25th percentile and the 75th percentile) as a measure of dispersion. Eighty-five percent of patients were discharged alive. Not unexpectedly recipients of allogeneic transplant experienced higher mortality. Eighty percent of allogeneic HSCT patients left the hospital alive while all but one (96%) of Table 1 Description of the HSCT population autologous transplant patients were discharged alive. Infections complicating GVHD were the principal cause of death in the majority of cases in which death occurred within the first 2 months (five deaths from sepsis in the allogeneic group, one in the autologous group). Interstitial pneumonitis (2) and multiorgan failure (3) caused death in the remainder of the allogeneic deaths; no infection was proven in these cases.
Results

Characteristics and outcome of the pediatric HSCT patients
Fever and neutropenia
Neutropenia was universal and the incidence of fever and neutropenia was Ͼ98% (74 of 75 transplants). The median day of onset of fever was the 4th day of neutropenia. During the period of neutropenia 40 patients (53%) had exacerbations of fever after initial improvement. The mode of the number of episodes of fever (initial fever plus recurrences/exacerbations) was one (33 patients), while the median was two and the mean was 1.85 Ϯ 1.18 (standard deviation). Table 2 summarizes the final diagnoses of the etiology of fever. Bacteremia without localized infection was the most common documented infection, present in 29% of episodes with fever. An additional 17% had central venous catheter-related infections associated with positive blood cultures. In nearly half of the cases (43%) the etiology of the fever was unexplained. Sixty-three percent of the fevers in the autologous transplant group were unexplained, while only 35% of the fevers in the allogeneic group were unexplained (P ϭ 0.045 Fisher two-tailed exact test). The difference is accounted for by an increased incidence of catheter-related infections and bacteremias in the allogeneic group. Of the 18 allogeneic transplant patients with unexplained neutropenic fevers only two had clinical evidence of graft-versus-host disease while neutropenic.
Blood cultures
The practice in our unit has been to obtain blood cultures from both peripheral veins and central venous catheters once daily when a patient is febrile. Table 3 summarizes the experience with blood cultures. In 37 of the transplants (49%) bacteremia was documented. Twelve of these 37 episodes had more than one organism isolated from blood (three episodes had more than one organism in a single set of cultures, and nine episodes had different organisms identified on different days). Bacteremia was significantly 
Three allogeneic HSCT patients with positive blood cultures also had evidence of viral infection. Two had stool cultures growing adenovirus; one had CMV viremia.
Bone Marrow Transplantation less common in the autologous transplants (29%) than in the allogeneic transplants (59%) (P ϭ 0.017). Ninety of a total of 461 sets of cultures (19.1%) were positive, ie at least one of the cultures drawn at a given time was positive. Most patients were febrile for more than 1 day and thus had multiple sets of blood cultures. Nineteen of 74 (26%) of the initial sets of cultures drawn before initiation of broad spectrum antibiotics were positive. Seventy-one of 387 (18%) sets drawn after the first day of fever were also positive despite treatment with systemic antibiotics. The difference was not statistically significant (P ϭ 0.145). Table 4 summarizes the frequency of positive blood cultures per day of fever. The majority of the positive blood cultures provided new diagnoses rather than corroborating bacteremia documented on previous days. Overall a total of 1077 blood cultures was obtained. Of these, 147 cultures (13.6%) were positive for pathogens, while an additional 12 blood cultures (1.1%) grew contaminants. Table 5 
Therapy
Empiric antibiotic therapy was generally initiated with ceftazidime and an additional gram-positive antibacterial antibiotic. In no episodes did the patient become afebrile within 24 h of initiation of antibiotic therapy. The duration of fever ranged from 3-59 days. Because of protracted fevers and blood culture results antibiotic regimens were modified for all but one patient (98%). The median number of modifications was four. In the group in which the source of fever was identified the median number of modifications was three, while in the group with the source of fever not identified the median number was five (P ϭ 0.0134 by median test). Fifty-seven episodes (76%) were treated with antifungal antibiotics. Twenty-five episodes (33%) received fluconazole alone, 10 episodes received amphotericin B (13%) alone, and 22 (29%) received them sequentially (fluconazole initially but later replaced by amphotericin). Three patients were excluded from the data in the 'source of stem cells' section: one autologous receiving marrow, one allogeneic receiving T-depleted marrow, and one allogeneic receiving both marrow and PBSC. 'Positive' indicates blood cultures in which organisms grew and which were compatible with the clinical circumstances; cultures growing organisms which in the judgment of the attending physician were contaminants were excluded. 'Set' indicates peripheral and CVC cultures drawn at the same date and time. Day 1 of fever was the first day the patient was febrile. Total sets drawn are the total number of sets of cultures drawn on a given day of fever. A set was deemed positive if any of the simultaneously drawn cultures was positive. Contaminants were not considered positive. The set was considered a new diagnosis if it produced an organism not identified in the previous sets of cultures. Cultures that grew an organism identified in the previous day's cultures were not considered new diagnoses. Table 6 summarizes duration of fever and time to engraftment. The median day of onset of fever was the 4th day of neutropenia. The median duration of fever in the entire group was 12.5 days. The majority of patients did not become afebrile until marrow recovery began. Only 18% of patients became afebrile 5 or more days before ANC reached Ͼ500 cells/l. Multiple regression analysis demonstrated that duration of fever was significantly associated with time to engraftment (P ϭ 0.0002). The median time to engraftment was 14 days, but there were substantial differences in the time to engraftment in subgroups. Multiple regression analysis of the entire group of transplants identified source of the cells (P ϭ 0.0263) and dose of CD34 ϩ cells/kg (P ϭ 0.0273) as being significantly related to the time to engraftment. The longest median fever and time to engraftment was seen in the group of umbilical cord blood recipients.
Duration of fever and neutropenia
Discussion
This review of pediatric HSC transplants showed that fever and neutropenia were nearly universal in the contemporary era of HSCT with post-transplant G-CSF support. This experience was similar to that of Dell'Orto et al 4 who reported a 100% incidence of fever in a series of pediatric allogeneic transplants, and Salazal et al, 5 Kolbe et al, 6 and Haahr et al 7 each of whom described Ͼ94% incidence of fever in adult autologous transplants. However, others have reported substantially lower incidences of fever. Mossad et al 8 reported a 35% incidence in adult autologous transplants while Lew et al 9 reported an approximate fever incidence of 80% in a group of adult autologous and allogeneic patients. A recent report by Krüger et al 10 of early infections in 409 adult transplant patients reported an incidence of fever of only 83% in a largely adult mixed allogeneic and autologous transplant population. It is difficult to explain these differences. Most of the series employed anti-63 Table 5 Organisms identified in blood cultures Numbers of organisms isolated in episodes and cultures exceeds number of positive episodes (37) and cultures (147) since multiple organisms were recovered from some episodes and cultures. The Candida and the Cryptococcus were isolated from the same patient.
biotic prophylaxis of some sort. Median durations of neutropenia were not consistently shorter in the series with lower incidences of fever. Each series had a heterogeneous population of patients treated with a variety of preparative regimens. However like many pediatric regimens the pre- IQ ϭ interquartile range (25th percentile-75th percentile).
Bone Marrow Transplantation parative regimens used in our series were very intensive. In addition, thiotepa was used in the majority of cases and severe mucositis requiring intravenous narcotics and parenteral nutrition complicated most transplants. 2, 3 We speculate that differences in regimen-related mucosal toxicity may explain some of the reported differences in the incidence of fever, since disruption of mucosal and skin barriers is a risk factor for infection.
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Bacteremia was very common, occurring in 49% of transplants. Other series have reported lower rates of bacteremia, ranging from 10-39%. [4] [5] [6] [7] [8] [12] [13] [14] This incidence of bacteremia was substantially greater than that observed in episodes of fever and neutropenia in non-transplant chemotherapy settings in which the bacteremia rate is approximately 15-20%. [15] [16] [17] The higher rate of bacteremia in our series could be related to the fact that antibacterial prophylaxis was not used for the majority of patients and/or that the preparative regimens used produced substantial toxicity to mucosa. 2, 3 As in these other recent series, gram-positive organisms were most commonly isolated, accounting for more than two-thirds of the isolates, and infection-related death was uncommon in episodes with gram-positive bacteremia.
Fever and neutropenia in pediatric HSCT patients varied substantially between subgroups of patients, and notable differences were seen in recipients of cells recently introduced into practice-cord blood and PBSC. Both duration of fever and time to engraftment were shorter in groups receiving PBSC compared to marrow consistent with other reports. 13, 18 Fevers were longest in duration in recipients of umbilical cord blood, and this was a reflection of the longer time to engraftment. Other recent studies of the use of umbilical cord blood have reported similar times to engraftment. 19 In our series the median duration of fever in the cord blood group was 27 days, compared to 15 in the allogeneic bone marrow, 10 in allogeneic PBSC, and six in autologous PBSC. The median days to ANC Ͼ500 were 24, 17, 13 and 11, respectively. Days to engraftment were related to the number of CD34 ϩ cells/kg. Since cord blood units are relatively small and most recipients are not infants, recipients of umbilical cord blood transplants will remain at higher risk for protracted neutropenia and more complex infections. The number of cord blood transplants is likely to increase in the near future given the reduced time needed to identify and obtain a unit for transplantation and the potentially lower risk of severe GVHD compared to unrelated PBSC or marrow transplants. It would seem prudent to develop aggressive infection prevention strategies in this group. Use of fluoroquinolones may reduce the risk of serious, gram-negative infections. These drugs are not widely used in pediatrics because of concern over reports of irreversible arthropathies in immature animals. We have used short courses of ciprofloxacin since 1996 in approximately 100 pediatric cancer patients and have observed no cases of severe, irreversible arthropathies. 20 We have observed one patient who experienced a brief episode of arthropathy that rapidly resolved with discontinuation of the drug. 21 There have been other reports of use of fluoroquinolones in other pediatric conditions (eg cystic fibrosis) without observation of substantial toxicity. 22, 23 Our data indicated that ciprofloxacin did not reduce the incidence of fever and neutropenia, but lower rates of bacteremia (especially with gram-negative organisms) were observed when it was used. Reductions in the incidence of gram-negative bacteremia have been reported in other studies employing oral quinolones. 7, 9, 10 Even if the incidence of fever is not reduced by use of prophylactic oral antibiotics we advocate their use since infection-related death rates are relatively uncommon with gram-positive organisms. Others do not endorse antibacterial prophylaxis with quinolones because of concern over the potential emergence of drug-resistant organisms. 24 To date this has not been a significant clinical problem in our transplant unit. However, the most important factor may be the CD34 ϩ cell dose available for transplantation. Selection of the largest available cord blood unit from among acceptably matched units may reduce the risk of protracted neutropenia.
Nearly one-fifth of all transplants were complicated by a central venous catheter-related infection. Dell'Orto et al 4 also observed a high rate of catheter-related infections in pediatric transplant patients. While CVCs make transplant feasible given the intensity of blood product, medication and nutritional support required during transplant, they substantially increase the risk of infection. Strategies for reducing the risk of CVC infections may reduce the cost and risks of transplant. At our center we are exploring the use of antibiotic-impregnated catheters and line flushes with minocycline-EDTA.
This analysis provides some insight into the cost-effectiveness of blood cultures in the transplant population and the practice of obtaining cultures daily while febrile. Overall 33 diagnoses of infection associated with bacteremia were made with 1077 cultures. Estimating that a blood culture may cost $75, the cost per positive diagnosis was approximately $2400. Nearly 20% of all sets of blood cultures were positive (ie at least one of the simultaneously drawn cultures was positive), a relatively high yield for a diagnostic procedure. Moreover, 18% of blood culture sets drawn after the initial day of fever were positive despite the concurrent treatment of the patient with broad spectrum antibiotics. Given the relatively high yield of blood cultures we recommend daily cultures for patients with persistent fever.
In nearly half the episodes the cause of fever was unexplained despite intensive investigation. Patients with no identified source of fever had more modifications of treatment regimens. In many cases this diagnostic uncertainty led to the empiric addition of antibiotics to provide activity against potential gaps in the treatment spectrum. While it is not clear that the addition of drugs improved outcomes, it is very likely that these additional drugs increased the total cost of treatment and possibly increased adverse effects in renal, hepatic and gastrointestinal function. While clinical research aimed at development of satisfactory empiric antibiotic regimens has substantially improved care, we believe additional investigation should be directed to development of rapid diagnostic methods in order to provide a basis for more focused therapy for the treatment of infections occurring during the neutropenia associated with hematopoietic stem cell transplantation.
